Pulmonx Corp LUNG
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-11.04
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $90.5M | -$54.0M | $67.1M | -$32.8M | $54.1M |
| 2024 | $83.8M | -$56.4M | $62.0M | -$33.0M | $85.8M |
| 2023 | $68.7M | -$60.8M | $50.8M | -$38.4M | $118.3M |
| 2022 | $53.7M | -$58.9M | $39.9M | -$46.4M | $154.0M |
| 2021 | $48.4M | -$48.7M | $35.6M | -$45.1M | $193.2M |
| 2020 | $32.7M | -$32.2M | $21.2M | -$31.5M | $226.1M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.04 (distress)
- Working capital / assets 0.631
- Retained earnings / assets -4.034
- EBIT / assets -0.415
- Equity / liabilities 0.72
Source: SEC EDGAR filings · CIK 0001127537 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.